Research on the Impact of Gonadotoxic Therapy

Individuals receiving gonadotoxic therapies due to oncologic, rheumatologic conditions, as well as transgender individuals undergoing puberty suppression and followed by cross-sex hormones may develop gonadal dysfunction and benefit from fertility preservation. To date, however, the risk/benefit analysis of fertility preservation has not been fully elucidated as the gonadotoxicity of many of these medications have not been well studied. The NICHD-PAG program is participating in a national clinical database of individuals who underwent ovarian tissue cryopreservation in order to learn about the risks and benefits of OTC. In addition, through collaborations with researchers within the National Cancer Institute we hope to evaluate the effects of newer agents on gonadal function.

top of pageBACK TO TOP